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a b s t r a c tThe evolution of organ transplantation has resulted in extended lifespan as well as better life quality of
patients with end-stage diseases, which in turn causes an increased demand for organs. The persistent organ
shortage requires a careful reconsideration of potential donors (living or cadaveric) that have current or
historical malignancies. Donors with low-grade skin tumors, carcinomas in situ of the uterine cervix,
and primary central nervous system (CNS) tumors can be considered as potential donors for recipients dying
on wait list longing for organ transplantation. Recently, transplant centers have turned to other types
of malignancies including low grade renal cell carcinoma, prostate, ureteral, endometrial and breast cancer,
and favorable outcomes have been shown in such innovations. When considering donors with a history of
malignancy, general biologic behavior of the tumor type, histology and stage at the time of diagnosis, and the
length of disease-free interval should be considered (Transplantation 2002;74(12):1657–1663). With the
review of literatures, we illustrate the organ utilization from donors with malignancies all around the world
since earlier times and give some suggestions for decision making under the circumstance of whether to
choose those marginal donors or not on the basis of reviewed literatures.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The persistent shortage of organ supplies is a major obstacle to carry
out organ transplantation for the large number of people waiting on the
list. Both the size of the candidatewaiting list and thenumberof deaths on
the waiting list are progressively increasing [1]. The disparity between
organ demand and organ supply has never been moderated. In order to
decrease the mortality on the waiting list, transplant centers make every
effort to increase the number of donors. Thus, utilization of extended
criteria donors (ECD) has been suggested [2]. In the early 2000s, the
conceptof extendedcriteria kidneydonorwasdeﬁned toolder individuals
with hypertension, diabetes, or renal dysfunction, who were expected to
produce allografts at greater risk of graft loss than standard donors, albeit
sufﬁciently adequate for transplantation [3]. While the deﬁnition of
extended criteria liver donor was characterized by individuals with
advanced age, steatotic livers, donation after cardiac death (DCD), livers
with seropositivity for hepatitis B virus (HBV) andhepatitis C virus (HCV).
Besides, occult malignancies become a part of extended criteria donor
factors [4]. Using organs from donors withmalignancy is not uncommon,
and it has plays an important role in expanding the donor pool. Though⁎ Corresponding author at: Third Xiangya Hospital, No 152 Tongzipo Road, Changsha
City, Hunan Province, P.R. China, 410013. Tel.: +86 15116316345; fax: +86
7318618365.
E-mail address: ye.qifa@yahoo.com (Q. Ye).
1 No conﬂict of interest.
http://dx.doi.org/10.1016/j.trre.2014.06.002
0955-470X/© 2014 The Authors. Published by Elsevier Inc. This is an open access article uthis may carry risk of malignancy transmission, the risk of tumor
transmission or donor related death is extremely small when compared
with the beneﬁts of organ transplantation.
2. Review of the literature
Buell et al. [5] reviewedall cases reported to the IsraelPenn International
Transplant Tumor Registry (IPITTR) that demonstrated a potential for
donor-transmitted malignancy from the year 1965 to 2003. 296 cases of
high-risk transplants performed using donors with known or incidentally
discoveredmalignancies were reviewed. From the overall series, 124 cases
(42%) were identiﬁed with conﬁrmed donor transmission. Among them,
CNS tumor, malignant melanoma, choriocarcinoma, renal cell carcinoma
(RCC), lung cancer, colon cancer, and breast cancer were discovered with
donor malignancy transmission. The transmission rate ranges from 23% to
93%. This study showeda relativelyhigher rate of tumor transmission, given
that the donors might have high grade malignancies or misdiagnosed CNS
tumors, which carry a much higher transmission risk.
Later, an analysis of Organ Procurement and Transplantation
Network/United Network for Organ Sharing (OPTN/UNOS) data on
39,455 deceased donors from 2000 to 2005 showed 1069 donors had
a past history of malignancy, resulting in 2508 transplants. The most
common type of previous cancer in the donor was nonmelanoma skin
cancer (n = 776) followed by central nervous system malignancies
(n = 642) and carcinoma of the uterine cervix (n = 336). Four
recipients died from donor transmitted malignancy. However, thesender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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against the 39,519 deaths on the waiting list during the same period
of time. Donors with a past history of cancer may be particularly
appropriate for urgent or high risk recipients such as Status 1 hearts
or livers. Although the 2508 organ transplants from donors with a
past history of cancer constitute only 2.2% of the 113,167 deceased
donor organs transplanted from 2000 through 2005, they resulted
in successful transplants and improved length and quality of life for
many patients [6].
Another report from Italy found a similar overall cancer transmis-
sion rate of 0.2% (14 of 231) in transplant recipients from donors with
malignancy [7], while the Spanish National Transplant Organization
Registry reported transmission of malignancy in 10 of the 100 (10%)
cases of transplants performed using donors with knownmalignancy.
The transmission rates were supposed to be 6 per 10,000 related to
the global recipients [8]. The Disease Transmission Advisory Com-
mittee (DTAC) reviewed donor-transmitted malignancy in 2009.
There were a total of 15 reported donor transmitted malignancies in
transplant recipients from 55 donors. Six of these 15 patients died due
to the transmitted malignancy representing a death rate of 40% in the
tumor transmitted population [9]. An updated publication of the
United Kingdom Transplant Registry from 2001 to 2010 reported that
of 30,765 transplants from 14,986 donors, 15 recipients developed
donor-transmitted cancer, and 3 (20%) recipients with DTC died as a
direct consequence of cancer [10].
Recently, Fiaschetti et al. [11]evaluated theexperienceof theCentre-Sud
Transplant Organization (OCST) area using cadaveric donor with
neoplastic diseases from 2003 to 2010. 28 evaluated donors (8.2%)
were suitable for transplantation according to the histological types
andgrades. 45organswere retrieved (22 livers, 19 kidneys, 3 hearts, and
1 pancreas) and transplanted into 44 recipients. No donor-transmitted
tumor was detected among the recipients (Table 1).
Though the transmission rate varies in different areas and different
tumor types or even with the organs transplanted, the experience of
using donors with a history of malignancy seems to be favorable for
expanding the organ donor pool, and the donor related tumor death
rate is extremely small, particularly when compared with waiting-list
mortality. We will review the literatures regarding several types of
donor malignancies, hopefully to give some suggestions in decision
making under the difﬁcult circumstance of whether to choose the
marginal donors or not afterwards.
3. Risk category assignment to speciﬁc tumors
Since the early days of transplantation, the risk of transmission
of malignancy from donor to recipient has been recognized. In 2011,
the subcommittee to examine donor-relatedmalignancy transmission
(Malignancy Subcommittee) of the DTAC of OPTN /UNOS suggested
risk categorizations for speciﬁc tumor types (Table 2). Suggested
approach to donor utilization is given for each category, recognizingTable 1
Summary of publications analyzing transmission of tumor in recipients receiving solid
organs from donors with known malignancies.
Publication Total number
of recipients
Number of recipients
with tumor transmission
Transmitted
tumor rate (%)
Buell et al. (2004) 296a 124 41.9
Kuaffman et al. (2007) 2508 4 0.2
Zucchini et al. (2008) 231 14 0.2
Garrido et al. (2008) 100 10 10
Ison et al. (2009) 55 15 28
Rajeev et al. (2012) NAb 15 NA
Fiaschetti et al. (2012) 44 0 0
a These data were based on voluntary reporting and there may be a tendency for
centers to report interesting, unusual, or challenging cases.
b NA = not available.the primacy of individual clinical judgment and often emergent
clinical circumstances [9]. According to the third edition (May 2011)
of United Kingdom guidelines for living donor kidney transplantation
[12], recommendations regarding donor malignancy can be summa-
rized in Table 3.
4. Melanoma
Though rare, malignant melanoma is one of the most commonly
reported donor-derived malignancies and has a high transmission
rate and mortality when unwittingly transmitted to a recipient [5,13].
Buell et al. [5] reviewed the data from IPITTR and identiﬁed that two
donor tumor histologies with the highest certainty of transfer were
choriocarcinoma and melanoma. The malignant melanoma was
demonstrated with a 74% tumor-transmission rate and a resulting 58%
mortality. Earlier in the 1990s, Penn [13] recorded 11 donors with a
history of melanomawho provided organs for 20 recipients. Melanoma
transmission occurred in 16 recipients (75%), of whom 11 (68%) died
frommetastatic disease. The transmission rate is extremely highand the
caused death rate also cannot be ignored.
Stephens et al. [14] reported in 2000 of a transfer of malignant
melanoma from a single donor to four solid organ transplant
recipients (kidney, liver, heart). All the four recipients died from
metastatic melanoma. The donor was said to have died of cerebral
hemorrhage and had no history or physical signs of melanoma.
Similarly, Morris-Stiff et al. [15] reported three graft recipients (two
kidney and hepatic) who developed metastatic melanoma from a
cadaveric multi-organ donor who died from a subarachnoid hemor-
rhage. Two of the recipients presented with symptomatic metastatic
lesions and the third patient, despite being carefully monitored,
developed evidence of metastatic cutaneous melanoma. Two of the
patients died as a direct result of their melanomas. Both donors in
these two reports died of intracranial hemorrhage, and neither was
identiﬁed with a history of melanoma. These two studies demonstrate
the potential of melanoma to metastasize into any organ of the body
and the fatal results caused by its metastasis. This may also suggest
that donors who die from intracranial hemorrhage must be used with
caution in case of the undetected metastatic melanoma due to its
special biological behavior. As with another case, transmitted
malignant melanoma was reported following a renal transplantation
from a multi-organ donor [16]. The donor was a 48-year-old male
who died from a subdural hemorrhage and at the time of organ
collection there was no clinical evidence of melanoma. One of the
renal transplant recipients underwent nephrectomy with cessation of
immunosuppression after the lung transplant recipient presented
melanoma of donor-origin, and a 3 mm melanoma deposit was
shown in the resected kidney.
A history of melanoma is an absolute contraindication for a
patient to be eligible for organ donation because of the possibility of
late and ultra-late recurrence in melanoma [6,17], and late recurrence
has been reported even in patients who have had melanomas less
than 1 mm in thickness [18] and this possibility should be considered
during clinical evaluation [19]. The current recommendation for treating
donor-related melanoma in renal transplant recipients includes
cessation of immunosuppression, allograft rejection and nephrectomy.
As for non-renal transplant recipients, reduction of immunosuppression
and an immediate retransplantation may be the best strategy [20].
With all the literatures reviewed above, we can conclude that donors
with a history ofmelanoma should not beused as a source to expand the
donor pool.
5. Choriocarcinoma
Reports on choriocarcinoma transmission are rare, but the high death
rate related to transmitted choriocarcinoma though organ transplant
has been highlighted. Earlier from the IPITTR data, 14 recipients were
Table 2
Suggested risk categorizations for speciﬁc malignancy types from DTAC.
Risk category Malignancies
Minimal risk (b0.1% transmission) Basal cell carcinoma, skin
Squamous cell carcinoma, skin without metastases
Carcinoma in situ, skin (nonmelanoma)
In situ cervical carcinoma
In situ vocal cord carcinoma
Superﬁcial (noninvasive) papillary carcinoma of bladder (T0N0M0 by TNM stage) (nonrenal transplant only)
Solitary papillary thyroid carcinoma, ≤0.5 cm
Minimally invasive follicular carcinoma, thyroid, ≤1.0 cm
(Resected) solitary renal cell carcinoma, ≤1.0 cm, well differentiated (Fuhrman 1–2)
Low risk (0.1–1% transmission) (Resected) solitary renal cell carcinoma, N1.0 cm ≤ 2.5 cm, well differentiated (Fuhrman 1–2)
Low grade CNS tumor (WHO grade I or II)
Primary CNS mature teratoma
Solitary papillary thyroid carcinoma, 0.5–2.0 cm
Minimally invasive follicular carcinoma, thyroid, 1.0–2.0 cm
History of treated non-CNS malignancy (≥5 years prior) with N99% probability of cure
Intermediate risk (1–10% transmission) Breast carcinoma (stage 0 i.e. carcinoma in situ)
Colon carcinoma (stage 0 i.e. carcinoma in situ)
(Resected) solitary renal cell carcinoma T1b (4–7 cm) well differentiated (Fuhrman 1–2) stage I
History of treated non-CNS malignancy (≥5 years prior) with probability of cure between 90–99%
High risk (N10% transmission) Malignant melanoma
Breast carcinoma N stage 0 (active)
Colon carcinoma N stage 0 (active)
Choriocarcinoma
CNS tumor (any) with ventriculoperitoneal or ventriculoatrial shunt, surgery (other than uncomplicated biopsy),
irradiation or extra-CNS metastasis
CNS Tumor WHO grade III or IV
Leukemia or lymphoma
History of melanoma, leukemia or lymphoma, small cell lung/neuroendocrine carcinoma
Any other history of treated non-CNS malignancy either (a) insufﬁcient follow-up to predict behavior,
(b) considered incurable or (c) with probability of cure b90%
Metastatic carcinoma
Sarcoma
Lung cancer (stages I–IV)
Renal cell carcinoma N7 cm or stage II–IV
Small cell/neuroendocrine carcinoma, any site of origin
Active cancer not listed elsewhere
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13 of these recipients developed metastatic choriocarcinoma, with a
transmission rate of 93% and a resulting 64% mortality rate [21].
Choriocarcinoma is considered as a high aggressive cancer and is
unanimously rejected in organ donors.
Lately, Bruan-Parvez et al. [22] reported an accidental transmission
of placental choriocarcinoma from a multi-organ donor to 4 different
recipients (combined pancreas-kidney, kidney, liver, heart). The donor
was a26-year-oldwomanwhodied fromamassive cerebral hemorrhageable 3
revious cancer and ﬁtness for living donation.
Recommendation Type of cancer
Absolute contraindication Melanoma
Testicular cancer
Renal cell carcinoma⁎
Choriocarcinoma
Hematological malignancy
Lung carcinoma
Breast cancer
Monoclonal gammopathy
Possible donation Treated cancer with high probability
of cure after 5–10 years
(favorable classiﬁcation and staging)
e.g. colon cancer (Dukes A N5 years ago),
non-melanoma skin cancer, carcinoma-in-situ
of the cervix or vulva
⁎ In somecenters, donationmaybe consideredwhere there is a small (b4 cm)subcapsular
nal cell carcinomawithcompletebenchexcisionat the timeofdonor surgery andnodistant
read. (http://www.bts.org.uk/MBR/Clinical/Guidelines/Current/Member/Clinical/
urrent_Guidelines.aspx?hkey=a1eb37c5-3824-4836-b0b2-ad118479e53c).T
P
re
sp
Cat 7 months of pregnancy, and no abnormality was found in the
macroscopic examination of the donated organs. Choriocarcinoma of the
donor was detected 1 month after transplantation to the four recipients.
The authors conﬁrmed high transmission of choriocarcinoma and bad
prognosis in liver transplantation.
So it is risky to use donors with choriocarcinoma, and special
attention should be paid to women donors at childbearing age.
Besides, given that donors who died of cerebral hemorrhage may
carry the risk of metastatic choriocarcinoma, careful examination of
choriocarcinoma should also be taken in such donors.
6. CNS tumors
CNS tumors have been classiﬁed into four histologic grades by
the World Health Organization (WHO) [23,24]. Each year in the
United States, approximately 17,000 patients are diagnosed with
malignant primary brain tumors, and more than 13,000 succumb to
these diseases [25], and the summaries of tumor registry reports by
Penn and Buell [26,27] concluded that, in light of the unmet patient
need, organs from donors with central nervous system malignancies
should not categorically be rejected, but should be offered to recipients
with limited short-term life expectancy. Though commonly used inmany
transplant centers, whether it is safe or not still remains controversial as
the real risk of tumor transmission remains unknown [28].
According to UNOS data from 1992 to 2005, 1039 donors had
either a past cancer history of CNS tumors or the cause of death
recorded as CNS tumor [1,6], and only one of the donor with an active
glioblastoma multiforme was conﬁrmed to have transmitted fatal
tumors to three separate recipients (kidney, liver, lung) [29]. On the
contrary, Buell et al. reported a much higher risk of utilization of such
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to 2002. 62 organs were transplanted from 36 donors with CNS
malignancy, resulting in 14(23%) donor transmitted CNS malignan-
cies [28]. The signiﬁcant difference between the data of UNOS and that
of IPITTR causes controversy. The high calculated risk of CNS cancer
transmission in the IPITTR is thought to be caused by the underes-
timation of the denominator of the ratio [30]. Because the IPITTR is a
passive forum for voluntary reporting, there may be a tendency for
centers to report interesting, unusual, or challenging cases and as
such, the true denominator is not known. However, the UNOS registry
may suffer from underreporting [27].
In a retrospective review from 1992 to 2006, 42 donors diagnosed
with a CNS tumor were identiﬁed in liver transplantation. Twenty
(47.6%) of the CNS tumors were glioblastomamultiforme (astrocytoma
grade IV), 11 (26.2%) were other astrocytomas, and 1 (2.4%) was an
anaplastic ependymoma. Twenty (62.5%) neoplasms were grade IV
tumors, 8 (25%) were grade II tumors and 4 (12.5%) were grade III
tumors. Over 80% of the patients had at least 1 kind of invasive
procedure violating the blood–brain barrier, but the result shows no
difference in survival between recipients of grafts fromdonorswith CNS
tumors and recipients of grafts from donors without CNS tumors. The
authors conclude that grafts from such donors can be appropriately
used, particularly in patients who carry a high risk of mortality [31].
Similarly, a recent study reviewed 246 UK recipients of organs
taken from donors with CNS tumors and found no evidence of a
difference in overall patient mortality for recipients of a kidney, liver,
or cardiothoracic organ, compared with recipients of organs from
donors without a CNS tumor [32], and on the basis of a series of
assumptions, the authors even found the use of kidneys from a donor
with a primary CNS tumor could provide a further 8 years of life over
the ones waiting for a donor without CNS tumor, in addition to the life
years gained by the transplant itself.
Recently, the Malignancy Subcommittee of the DTAC committee of
OPTN/UNOS [19] suggested that low grade CNS tumors (WHOgrades I o
r II) and some high grade tumors such as glioblastomamultiformemay
have relatively low transmission rates, and suggested that such organs
may be usable for recipients at signiﬁcant risk without transplant. In
contrast, higher grade CNS tumors (WHO grades III–IV), or any CNS
tumor, regardless of grade, with ventriculoperitoneal or ventriculoatrial
shunt, prior surgery (excluding uncomplicated biopsy), chemotherapy,
radiotherapy or extra-CNS metastasis was provisionally placed into the
high risk category, anduse of organs fromthesedonorswasdiscouraged
except in rare and extreme circumstances. However, the increased
incidence of donor transmitted malignancy due to the misdiagnosed
brain death has to be taken into consideration, especially in donorswho
died from intracranial hemorrhage [5]. So it is signiﬁcant to conﬁrm the
etiology of brain death to reduce the probability of transferred
malignancy. Anyway, transmission from donors with CNS tumors is
quite rare and those donors in absence of the risk factors can contribute
to expanding the donor pool.
7. Renal cell cancer
Donors with renal cancer were not thought to be eligible for organ
transplantation at earlier time because of the high metastasis [5].
However, with the burden of increased population on the waiting list,
innovative strategies considering donors with small renal cell cancer
(RCC) have recently emerged.
The largest series of 43 cases are presented in 2008 from Princess
Alexandra Hospital by Nicol et al. [33]. 43 kidneys were transplanted
from 41 donors with small (b3 cm) RCC into patients who were
elderly or had signiﬁcant comorbidities between 1996 and 2007.
Among the 41 donors, 3 were deceased donors and 38 were donors
who underwent radical nephrectomy for a presumed RCC. Successful
results were shown in the report with kidneys transplanted
after excision of the RCC and conﬁrmation of no distant metastasis.Only one case showed tumor recurrence 9 years after transplantation
in the follow-up (mean 32 months). Furthermore, the study of
Brook et al. [34] has also showed favorable results on the utilization of
tumorectomized kidneys from patients with small, localized, inciden-
tally detected RCC. Both the patient and graft survival of such type of
renal transplant are comparable to that of conventional live unrelated
transplants, and display a signiﬁcant survival advantage for those who
would otherwise not receive a transplant. Also it is recommended that
detection of a small renal lesion during assessment of potential live
donor should not necessarily prevent transplantation proceeding [35].
Except for kidneys, livers from donor with RCC may also be used
for transplantation. As it was reported by Serralta et al. in 2003, 4
cadaveric donors with early-stage (T1–T2) renal cell carcinoma were
detected after implantation of the livers [36], but no evidence of
tumor transmission was observed in all the recipients after an average
follow-up of 51 months. Another study in 2009 also reported the
utilization of donor with genitourinary malignancy [37]. 2 donors
affected by low-grade RCC were classiﬁed as “standard risk” and
transplanted livers to recipients pending informed consent, with no
death consequent to a neoplastic disease. Both studies showed great
results of liver use from donors with genitourinary cancer.
Review of cases of cardiothoracic transplant recipients of an organ
from a donor with renal malignancy showed that renal cell
carcinomas without capsular invasion did not result in tumor
transmission. However, in the case of vascular invasion of the tumor
in the donor, tumor transmission appears to be early [36]. Buell and
colleagues [38] reported on 5 recipients of cardiothoracic organs from
the same registry who received organs from donors with a renal-cell
carcinoma. Two tumors that presented initially with vascular invasion
led to metastatic spread in the recipients, whereas 3 tumors were
small and contained within the renal capsule and did not develop
metastases after a follow-up of 30–70 months. Moreover, in a report
from France, a cadaver donor with renal cell adenoma in one kidney
donated another kidney and heart. The kidney recipient was tumor
free, while the heart recipient died sevenmonths after transplantation
due to metastasis from renal cell carcinoma [39].
It seems that those incidentally discovered, small RCC with low
histological grade (Furhman grades I and II) have a relatively low
potential for aggressive clinical behavior, and it has become the
general consensus [40]. However, a full discussion with the patient
and family are essential before transplantation about the risk of
receiving such organs, which may include tumor recurrence or
metastases and so on. Besides, kidneys from patients with small
renal tumors who have elected to undergo radical nephrectomymight
provide a valuable resource for many patients with end-stage renal
failure, but the utility of these organs should not inﬂuence the
decision of the donor with a renal tumor about their surgery [33].
With the review of the literature, we believe that kidneys (or livers)
from donors with small, incidental RCC as well as RCC heart donors
without capsular invasion can be safely used and will become a
novel source for transplantation, and thus, expand the constrained
donor pool.
8. Prostate cancer
Prostate cancer is the most prevalent malignancy in males over
60 years old, and the use of elderly donors may consequently carry
the risk of presented prostate cancer. However, donors with prostate
cancer now do not seem that contraindicated as it was before. The
acceptance of organs from donors with prostate cancer was ﬁrst
introduced in the Emilia-Romagna Region of Italy in 2001 [41]. Before
then, all candidate donors with prostate cancer were excluded, as the
risk of neoplastic transmission among recipients who received organs
from donors carrying prostate cancer was pretty high (29%) [42]. The
revised Italian National guidelines in 2005 recommend an acceptance
of potential candidates with prostate cancer to extend the donor pool
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with localized and Gleason score ≤6 prostate cancer are deﬁned as
the “standard risk” category in the new guidelines [44].
However, just from present literatures, it is still difﬁcult to
guarantee the absolutely safety of widespread utilization of donors
with prostate cancer. As it is commented by the European guide for
safety and quality assurance for transplantation “There is no written
consensus regarding the procedure for donors with prostate carcinoma.
The procedure should be individualized assessing the characteristics of
the donor and the condition of the recipient.” [45]. Still, donors with
prostate cancer may be a new source in the endeavor to decrease the
disparity between the available organs and recipients on thewaiting list.
9. Ureteral cancer
Mitsuhata [46] reported 3 cases of successful renal transplantation
from live-related donors with lower ureteral cancer. The tumors were
excised and the margins of the remaining ureters were free of cancer
by frozen section detection. These ureteral cancers were at low-grade
in histology. All recipients survived without cancer recurrence for
62–109 months. In a subsequent study [47], the authors reviewed all
8 kidney transplants using living donors with ureteral cancers, and
there was only one recurrence of ureteral cancer in the transplanted
kidney 15 months after operation.
Both reports may suggest that organs from donor with low-grade
lower ureteral cancer can be used for transplantation with informed
consent in the condition of severe shortage of donor organs.
10. Endometrial cancer (EC)
EC is the most commonmalignancy of the female genital tract, and
is typically seen in post-menopausal women [12]. Patients with EC
are always diagnosed at early stages and have a good prognosis with a
5-year overall survival rate greater than 85% [48]. To our knowledge,
reports about organ transplants from donorswith EC are quite limited,
and no transmission of cancer has ever been recorded through
transplantation from such donors. As recorded in the OPTN/UNOS [6],
65 deceased donor transplants were from donors with a history of
uterine EC from 2000 to 2005, and three of them had a cancer-free
interval less than 5 years. Though no detail is acquired about the stage
or histological type of the cancer, there was no transmitted cancer
occurred from donors with EC. While according to the review from
Kälble et al., donors with a past history of endometrial cancer are
placed into the intermediate risk category (10–25%) along with
patients with colon, breast and prostate cancers [49]. Still, more
studies are needed to estimate the risk of recurrence of using such
donors in organ transplantation.
11. Breast cancer
Breast cancer is the second highest cancer-related cause of
mortality in the United States, second only to lung cancer. Donors
with a past history of breast cancer are placed into the high risk
category and are suggested be avoided despite curative resections
due to the potential late metastases, but patients with a history of
stage T1a or T1b breast cancer in remission for 10 or more years may
be taken into consideration [20].
An early review from the IPITTR noted a donor tumor transmission
rate of 29%. Tumor transmission was only noted in cases involving
invasive breast cancer, and was not associated with in situ carcinomas,
such as ductal carcinoma in-situ (DCIS), and lobular carcinoma in-situ
(LCIS). As with melanoma, breast cancer is notorious for late and
aggressive recurrences. For this reason, the use of donors with a history
of breast cancer should be limited to those with non-invasive forms,
such as DCIS and LCIS, or those with early-stage invasive lesions who
have completed an extended disease-free interval [5]. According to theOPTN/UNOS data from 2000 to 2005, 126 deceased donor transplants
were fromdonorswith ahistoryofbreast cancer, and21(16.7%)of them
had a cancer-free interval less than 5 years [6].
Currently, there is no existing guideline to show the duration of
recurrence-free survival time for breast cancers before it is safe for
them to undergo transplantation. Usually, a transplant team would
evaluate such patients in great detail to rule out any clinical or
radiological signs or symptoms of recurrence before transplantation.
Also, most centers would wait from 2 to 5 years for recurrence-free
interval before subjecting a patient to transplantation. Penn et al. [50]
retrospectively examined 1297 cases of pre-existing malignancies in
renal transplant patients. A recurrence rate of 21% was found in
patients who were successfully treated before renal transplant
and he suggested that a waiting period of 5 years was desirable for
breast cancer.
12. Lung cancer
Published risk factors based on OPTN data provided a foundation for
assigning lung cancer to the high risk category. Of the report received by
the OPTN, seven donors with a history of lung cancer donated their
organs between 2005 and 2007. Lung cancer transmission occurred
in three recipients, of whom two died from metastatic disease [9].
This result collaborated with the data from IPITTR by which lung cancer
was identiﬁed as high risk (41%) for donor transmission.
As recorded in the OPTN/UNOS [6], a cancer-free interval of only
0–5 years was reported for 30% of the lung cancers, but the total
number was only 10 tumors.
Recently, a large series of 30,765 transplants from 14,986 donors
were presented by Rajeev and colleagues. 18 recipients developed
donor transmitted cancer, and 5 were lung cancer [10]. According to
the author, donor transmitted lung cancer is rare but frequently
results in graft loss and death which showed the importance to
highlight the rarity of transmission and also the possible outcome
when such transmission does occur.
13. Hematologic malignancies
Transmission of hematologic malignancies in solid organ trans-
plants is rare, and has been reported in the literature only a handful of
times. However, based on the data from DTAC and OPTN/UNOS,
donors with a past history of leukemia or lymphoma have relatively
high tumor transmission rates [9], and the consequences of
transmission of hematologic malignancies can be devastating to the
organ recipient, and present a particular challenge to those patients
receiving life-saving organs such as liver, heart or lung, due to the
necessity of retaining the transplanted diseased organ.
A total of 154 events have been reported through the Patient Safety
System between 2005 and 2007. There were 65 reports (42%) of
unexpected malignancy related events made to the OPTN. According
to the study, 4 recipients were conﬁrmed to have donor-transmitted
lymphoma and two of them died as the result of lymphoma
transmission [9]. In addition to lymphoma, acute promyelocytic
leukemia has been transferred by the transplantation of a cadaveric
liver allograft [51], metastatic glioblastoma multiforme has been
transferred in kidney and liver transplants [52,53], and acute myeloid
leukemia has been transmitted by the transplantation of donor bone
marrow [54].
In 2008, Harbell et al. reported a case of anaplastic T-cell
lymphoma transmitted to four recipients of solid organ transplants
from a DCD donor suspected of having bacterial meningitis [55]. The
transplanted kidneys and pancreas were excised from the respective
recipients, and the kidney and pancreas recipients responded well
to chemotherapy. The liver recipient underwent three cycles of
chemotherapy, but later died due to complications of severe tumor
burden. It is concluded that lymphoma can masquerade as other
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lymphoma transmission, excision of the graft may be the only chance
at long-term survival.
14. Other intra-abdominal cancers: hepatocellular, pancreatic and
colorectal cancer
The utilization and report of donors with a history of hepatocellular,
pancreatic or colorectal cancer are low due to various reasons, but we
still noticed that there were some anecdotal reports.
The UNOS transplant data 1997–2002 illustrated that in 27,846
isolated liver transplantations, there were 10 cases of donor related
malignancy [56]. Later, a series of 69 cases of transmission of donor
malignancy were reported by IPITTR and no transmission was
identiﬁed in organ recipients from donors with hepatobiliary
malignancies [42]. It should be pointed out that some benign tumors
have the potential to undergo malignant transformation, and
this should be kept in mind when such tumors are encountered.
For example, some hepatocellular adenoma subtypes (particularly
beta-catenin-expressing [55]) have a signiﬁcant risk of hepatocellular
carcinoma, which has the potential to lead to nonoptimal triage of
donor organs.
In 2001, Roza et al. reported the ﬁrst known combined kidney-
pancreas recipient who developed adenocarcinoma in the trans-
planted pancreas [57]. Later, Gerstenkorn and colleagues reported a
case of a pancreatic adenocarcinoma of donor origin presented as
lymphangitis carcinomatosa of the lung in a renal transplant recipient
9 months after transplantation, which is likely to have contributed to
the death of the patient 15 months after transplantation[58]. In 2009,
DTAC summarized the data fromOPTN/UNOS between 2005 and 2007
and 65 cases of unexpected malignancy related events were reported.
There was only one pancreatic adenocarcinoma transmission [9].
Despite the limited information about the transplantation of donors
with a history of pancreatic or hepatocellular cancer, uncertainties exist
in the utilization of these donors, and the risk categories of these
malignancieswere not assignedby theDTACMalignancy Subcommittee
[19]. In the absence of good quality evidence, preoperative screening
should be personalized and based upon the individual's risk, clinical
history, and preference.
Colorectal cancer represents the second most common cancer in
women and third most common in men. Donors with a past history of
colon carcinoma are placed into the high risk category for donor
tumor transmission by the DTAC [9]. The Israel Penn International
Transplant Tumor Registry covering a period between 1965 and
2003 reports two cases of donor-transmitted colon cancer [5]. In 2004,
the OPTN/UNOS analyzed 108,062 recipients from 34,933 donors for
a period of 51 months and reported 15 cases of donor-transmitted
cancer, including only one case of transmitted colon cancer [59].
Similarly, the United Kingdom Transplant Registry reported 30,765
transplants from 14,986 donors in 2012 and also found only case of
transmitted colon cancer [10]. Interestingly, not every diagnosed
malignant tumor in the donor is necessarily transmitted to the
recipient; the UNOS registry (2005–2007) [9] reporting one donor with
proven colon cancer without transmission to the recipient. Feng et al.
concluded thatpotential donorswithahistory of colon carcinoma in situ
(stage 0) could provide organswithout any disease-freewaiting period,
but donorswith a history of stage 1 (T1–T2) colon cancerwould require
a variable disease-free interval, or may never be able to serve as donors,
depending upon differences in tumor recurrence and survival rates
based on gender and race [60].
14. Discussion
The success of solid organ transplantation is accompanied by a
severe shortage of available organs for those currently awaiting
transplantation. In recent years, many programs have implementedthe aggressive use of extended criteria donors, being of either
malignancy or viral infections. However, donor-transmitted
malignancy has been increasingly reported as a complication of
organ transplantation.
Compared with the beneﬁts of organ transplantation, the risks for
tumor and disease transmission are small; however, donors with a
past history of aggressive tumors, such as breast cancer, melanoma,
and choriocarcinoma may possess the potential of unpredictable
recurrence. The use of donors with extended disease-free intervals
after curative breast or uterus surgery must be made after a detailed
review of the pathology reports, and even then, should be done with
informed consent of the recipient. However, patients with a history of
CNS tumor without active disease are not segregated into risk
categories in organ donation, and tumor donors with prostate cancer,
low-grade lower ureteral cancer, EC, and T1a or T1b breast cancer in
remission for 10 or more years may also contribute to expanding the
donor pool. Besides, the use of organs from donors with in situ cancers
can be considered with minimal hesitation and informed consent [5].
Still, using organs from donors with malignancy may carry the
chance of tumor transmission. Once a donor-transmitted malignancy
is suspected, in situ hybridization for sex chromosomes, HLA typing,
DNA polymorphism or microsatellite analysis can be used to
differentiate donor from recipient origin of tumors [19]. If one
recipient develops cancer from a multi-organ donor, it is essential to
make other recipients informed of the risk of tumor transmission and
take measures before it is too late. Immunosuppression should be
ceased or minimized when donor tumor transmission occurs [6].
Renal or pancreatic recipients may have cessation of immunosup-
pression and grafts removal together with adjuvant therapy. For liver
recipients, if transferred cancer is limited to the organ, partial
hepatectomy or retransplantation can be life-saving. However, as for
cardiac and lung recipients, immunosuppression should be lowered
and antineoplastic therapy should begin, while retransplantation
is considered [42,48].
In conclusion, a careful individualized risk–beneﬁt assessment
for using organs from donors with malignancy should be made and
presented to the recipients before transplantation, and a fully
informed consent is mandatory in any circumstance where risk is
considered to exceed standard expectations [42]. More precise
evaluation for the risks of tumor transmission from donors with
malignancy will be obtained through the global updated data in the
future. With careful selection and analysis, donors with malignancies
will hopefully act an important role in easing the organ shortage and
diminishing the mortality on the wait-list.
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